Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Multicentre, Randomized, Three-Period, Three-Treatment, Cross-Over Study to Evaluate the Effect of BGF MDI, BFF MDI, and Placebo MDI on Exercise Parameters in Participants With COPD (ATHLOS)

NCT06067828 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06067828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06067828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Multicentre, Randomized, Three-Period, Three-Treatment, Cross-Over Study to Evaluate the Effect of BGF MDI, BFF MDI, and Placebo MDI on Exercise Parameters in Participants With COPD (ATHLOS)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
October 24, 2023
Completion date
January 22, 2026
Enrollment
171 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease